HRSA Names Manufacturers Approved for Expanded 340B Rebate Pilot
HRSA has disclosed which drug manufacturers are approved to participate in a revised 340B rebate pilot, under which ten drugmakers will shift 21 drugs from upfront discounts to after-the-fact rebate payments starting next year. The change expands on the administration's earlier rebate pilot attempt. Covered entities purchasing these drugs through 340B will need to pay full price at the point of sale and later seek rebates, rather than receiving discounts immediately. The shift takes effect at the start of next year.
Covered entities, including safety-net providers and clinics serving Medicaid patients, face cash-flow and administrative burdens from paying full price upfront and waiting for manufacturer rebates on 340B drugs.
Pharmacy
You might also like